Obesity and Mortality of Critically Ill Patients With COVID-19 — COV-OB-ICU  

Obesity Clinical Trial

Official title: Obesity as a Risk Factor for Mortality of Critically Ill Patients With Coronavirus Disease 2019 (COVID-19): a Cohort Study of the First Wave in Nancy, France

Status Completed

Clinical Trial Summary

Disproportionate impact of COVID-19 in patients with obesity is now well established.

Obesity is associated with severe forms of COVID-19 and may be a risk factor of intensive care unit (ICU) admission. Obesity is associated with COVID-19 related hospital death in a large United Kingdom cohort study. However, there is a gap of knowledge on assessment of outcomes such as severity of Acute Respiratory Distress syndrome (ARDS), duration of hospitalisation and mortality in ICU. Moreover, an obesity survival paradox has been observed in patients with ARDS. This raises the question whether the obesity paradox has been broken by COVID-19.

The investigators aim to explore risk factors of in-ICU death for patient with COVID-19, including obesity and other chronic diseases and to describe the clinical course and outcomes, including the management of acute respiratory failure and other intensive care management.

Clinical Trial Description

The investigators aim to report ICU mortality for patients according to BMI category and to describe the detailed ICU clinical course of illness :

• Risk factors for ICU mortality : age, sex, baseline comorbidities

• Causes of death

• Risk factors for use of non invasive mechanical ventilation

• Non-fatal outcomes

• Ventilator-free days

• ICU length of stay. ;

Related Conditions & MeSH terms

• Comorbidities and Coexisting Conditions
• Coronavirus Infections
• COVID
• Critical Illness
• Obesity
• Severe Acute Respiratory Syndrome

• NCT number: NCT04425213
• Study type: Observational
• Source: Central Hospital, Nancy, France
• Status: Completed
• Start date: May 12, 2020
• Completion date: May 26, 2020